Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy

Immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, have improved survival of patients with multiple myeloma (MM). However, these therapies are associated with an increased risk of venous thromboembolism (VTE). Apixaban has been approved for treatment of acute VTE...

Full description

Bibliographic Details
Main Authors: Robert Frank Cornell, Samuel Z. Goldhaber, Brian G. Engelhardt, Javid Moslehi, Madan Jagasia, Daryl Patton, Shelton Harrell, Robert Hall, Houston Wyatt, Greg Piazza
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Oncology
Subjects:
Apixaban (Eliquis®)
myeloma
anticoagulation (AC)
immunomodualtors
venous thomboembolism
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00045/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00045/full

Similar Items